Current stage-Stage IV - Page 2 of 38 Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

Posted by on Aug 8, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...

Read More

Evaluating the safety and effectiveness of nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

Evaluating the safety and effectiveness of nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

Posted by on Aug 7, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of nivolumab (Opdivo) in combination with carboplatin (C; Paraplatin) and paclitaxel (P; Taxol) plus bevacizumab (B; Avastin) as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The data showed that nivolumab plus BCP...

Read More

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Posted by on Aug 7, 2021 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...

Read More

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Posted by on Jul 31, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of...

Read More

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Posted by on Jul 25, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients. Some background Colorectal cancer (CRC) is one of...

Read More

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Does neratinib plus capecitabine benefit patients with HER2-positive breast cancer spread to the central nervous system?

Posted by on Jul 25, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of neratinib (Nerlynx) plus capecitabine (Xeloda) versus lapatinib (Tykerb) plus capecitabine in patients with human epidermal growth factor (HER2)-positive breast cancer (BC) spread (metastases) to the central nervous system (CNS; brain and spinal cord). The data showed that the...

Read More

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Which factors could predict immunotherapy outcomes in patients with advanced melanoma?

Posted by on Jul 24, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated if there were any clinical indicators to identify which patients with advanced melanoma would benefit from immune checkpoint blocker (ICB) therapy. The data showed that blood LDH levels, the extent of disease, number of white blood cells, and immune-related side effects were all associated with better...

Read More

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Is pyrotinib with vinorelbine effective in treating HER2+ metastatic breast cancer?

Posted by on Jul 21, 2021 in Breast cancer | 0 comments

In a nutshell This study was carried out to examine the safety and effectiveness of pyrotinib (Irene) in combination with vinorelbine (Navelibine) is in treating metastatic breast cancer (BC). The authors found that this treatment combination showed promising results and was well tolerated in these patients.  Some background BC is...

Read More

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Posted by on Jun 12, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...

Read More

Adding everolimus to letrozole in premenopausal patients with hormone-positive advanced breast cancer

Adding everolimus to letrozole in premenopausal patients with hormone-positive advanced breast cancer

Posted by on Jun 6, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects and outcomes of adding everolimus (EVE; Afinitor) plus letrozole (LET; Femara) to hormonal therapy for the treatment of premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (BC). The data showed that the combination of EVE+LET improved survival...

Read More

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients.  Some background Lung cancer...

Read More

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This review was carried out to analyze the effectiveness and safety of EGFR tyrosine kinase inhibitors (TKIs) plus chemotherapy (CT) versus EGFR-TKIs alone as a treatment for advanced non-small-cell lung cancer (NSCLC) that is EGFR-positive. The authors found that EGFR-TKIs and CT treatment improved survival for these patients while...

Read More